Cited by 573Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Open access

Kelly, Karen, Chansky, Kari, Gaspar, Laurie E., Albain, Kathy S., Jett, James, Ung, Yee C., Lau, Derick H.M., Crowley, John J., Gandara, David R.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.4824

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to evaluate in a maintenance setting in stage III disease. PATIENTS AND METHODS: Untreated patients with stage III NSCLC, a performance score of 0 to 1, and adequate organ function were eligible. All patients received cisplatin 50 mg/m(2) on days 1 and 8 plus etoposide 50 mg/m(2) on days 1 to 5, every 28 days for two cycles with concurrent thoracic radiation (1.8- to 2-Gy fractions per day; total dose, 61 Gy) followed by three cycles of docetaxel 75 mg/m(2). Patients whose disease did not progress were randomly assigned to gefitinib 250 mg/d or placebo until disease progression, intolerable toxicity, or the end of 5 years. The planned sample size was 672 patients to confer power of 0.89 to detect a 33% increase over the expected median survival time of 21 months (one-sided P = .025, log-rank test). Random assignment was stratified by stage, histology, and measurable versus nonmeasurable disease. RESULTS: Enrollment began in July 2001. An unplanned interim analysis conducted in April 2005 rejected the alternative hypothesis of improved survival at the P = .0015 level for 243 randomly assigned patients. The study closed, and preliminary results were reported. Now, with a median follow-up time of 27 months, median survival time was 23 months for gefitinib (n = 118) and 35 months for placebo (n = 125; two-sided P = .013). The toxic death rate was 2% with gefitinib compared with 0% for placebo. CONCLUSION: In this unselected population, gefitinib did not improve survival. Decreased survival was a result of tumor progression and not gefitinib toxicity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.4824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490

Show all 31 references

Sorted by citations

Items 401–500 of 573

The changing landscape of stage III lung cancer: a literature review
Patel, M., Bruno, D. S., Grubb, W., & Biswas, T. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1796645 · Cited by 4
Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?
Wauters, E., & Vansteenkiste, J. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.05.16 · Cited by 4
Les promesses de la radiothérapie. Focus sur les tumeurs pulmonaires
Jouin, A., Durand-Labrunie, J., Leroy, T., Pannier, D., Wagner, A., Rault, E., & Lartigau, E. F. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1760 · Cited by 4
Reasoning the Effect of Immunotherapy After Chemoradiation in the PACIFIC Trial
Bulbul, A., & Araujo-Mino, E. P. (2018) · Future Oncology · doi:10.2217/fon-2018-0464 · Cited by 4
EGFR Gene Mutations: Is it Prognostic or Predictive in Surgically Resected Lung Cancer?
Mitsudomi, T., & Tada, H. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182743a0c · Cited by 4
SWOG S0023: What Meets the Eye May Be Only Half the Truth
Bhutani, M., Pathak, A., & Mao, L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.4218 · Cited by 4
[Current Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted Therapy].
Zhang, G., Wang, H., Zhang, M., Li, P., & Ma, Z. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.09.10 · Cited by 3
Place des traitements ciblés dans la prise en charge des cancers broncho-pulmonaires
Staudacher, L., Teixeira, L., Kempf, E., Rousseau-Bussac, G., Jouveshomme, S., Cohen, R., Beuzelin, C., Jagot, J.-L., Salmerón, S., & Trédaniel, J. (2012) · Pathologie Biologie · doi:10.1016/j.patbio.2012.05.011 · Cited by 3
Concurrent Chemoradiation for Elderly Patients with Locally Advanced Non-Small-Cell Lung Cancer: Still a Controversial Issue
Westeel, V., Quoix, É., Baudrin, L., & Milleron, B. J. (2012) · Aging Health · doi:10.2217/ahe.12.14 · Cited by 3
State of the art of radiotherapy.
Garrido, P., & Olmedo, M. E. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.02 · Cited by 3
[Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel Administrated Every Three Weeks in Inoperable Advanced Non-small Cell Lung Cancer: A Retrospective Study from A Single Center].
Zhao, J., Zhang, X., Hu, K., Wang, H., Xu, Y., Si, X., Zhong, W., Huang, X., Zhang, L., & Wang, M. (2016) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2016.11.03 · Cited by 3
The Conundrum of Adjuvant HER2 Treatment Options
Bulbul, A., Araujo-Mino, E. P., & Dayao, Z. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00177 · Cited by 3
Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
Loh, J., Low, J. L., Sachdeva, M., Low, P. Q. J., Wong, R. S. J., Huang, Y., Chia, P. L., & Soo, R. A. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2245140 · Cited by 3
Impact assessment of expanding the utilization of novel antineoplastic drugs for lung cancer treatment on key performance indicators of the Federal project «Cancer control»
Александрович, А. Н., Makarov, A. S., & Sisigina, N. (2023) · Voprosy Onkologii · doi:10.37469/0507-3758-2023-69-3-538-548 · Cited by 3
The Role of Consolidation Treatment in Locally Advanced Unresectable NSCLC
Fakhrejahani, F., Sadraei, N. H., & Mekhail, T. M. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0330-8 · Cited by 3
Radiochemotherapy in Locally Advanced Nonsmall-Cell Lung Cancer
Jeremic, B. M., Casas, F., & Hervas, A. (2011) · Medical radiology · doi:10.1007/174_2011_232 · Cited by 3
From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions
Koning, C. C. E., Belderbos, J. S. A., & Uitterhoeve, A. L. J. (2010) · Chemotherapy Research and Practice · doi:10.1155/2010/506047 · Cited by 3
The evolution of phase I trials in cancer medicine: a critical review of the last decade
Tolcher, A. W. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10133 · Cited by 3
Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów
Jassem, J., Biernat, W., Bryl, M., Chorostowska‐Wynimko, J., Dziadziuszko, R., Krawczyk, P. A., Kordek, R., Kowalski, D. M., Krzakowski, M. J., Olszewski, W. T., et al. (2014) · Advances in respiratory medicine · doi:10.5603/piap.2014.0019 · Cited by 3
Immunotherapy for Lung Cancer—Improving Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer With Immunotherapy
Sun, L., & Aggarwal, C. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000485 · Cited by 3
Combined Radiation Therapy and Chemotherapy as an Exclusive Treatment Option in Locally Advanced Inoperable Non-small Cell Lung Cancer
Jeremic, B. M., Dubinsky, P., Milisavljevic, S. S., & Kiladze, I. (2021) · Medical radiology · doi:10.1007/174_2021_277 · Cited by 3
Adding Immunotherapy and Targeted Therapy to Chemoradiotherapy for Non-small Cell Lung Cancer
Ozair, M. Z., & Ohri, N. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.09.002 · Cited by 2
Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms
Eberhardt, W., Gauler, T. C., Welter, S., Krbek, T., Stuschke, M., & Pöttgen, C. (2011) · Der Onkologe · doi:10.1007/s00761-011-2035-7 · Cited by 2
Oncology Scan—Thoracic Cancers
Machtay, M. X., Schipper, M. J., & Kong, F. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.01.008 · Cited by 2
Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM
Pirker, R. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.05.54 · Cited by 2
Consolidation Systemic Therapy in Locally Advanced, Inoperable Nonsmall Cell Lung Cancer—How to Identify Patients Which Can Benefit from It?
Jeremic, B. M., Mariamidze, E., Shoshiashvili, I., & Kiladze, I. (2022) · Current Oncology · doi:10.3390/curroncol29110656 · Cited by 2
Combined chemoradiotherapy regimens and their effectiveness in the treatment of patients with non-small-cell unresectable stage III lung cancer: review of literature
Мариниченко, Н. В., Лактионов, К. К., Назаренко, А. В., Breder, V. V., Borisova, T. N., Yudin, D. I., Сергеевич, А. М., Egorova, A. V., & Федорова, А. А. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-10-92-98 · Cited by 2
Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy
Vrankar, M., & Stanič, K. (2018) · Radiology and Oncology · doi:10.1515/raon-2018-0009 · Cited by 2
[Clinical developments for the EGFR-TKI combined with radiotherapy in advanced non-small cell lung cancer].
Li, X., & Zhu, G. (2014) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2014.04.12 · Cited by 2
Future directions in multimodality therapy for NSCLC
Tsao, A. S., Roth, J. A., & Herbst, R. S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.174 · Cited by 2
A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China
Yang, L., Wang, Z., An, T., Bai, H., Zhao, J., Duan, J., Li, P., Wu, M., Sun, H., Liang, L., et al. (2010) · Chinese Journal of Cancer Research · doi:10.1007/s11670-010-0001-3 · Cited by 2
Gefitinib in non-small-cell lung cancer-an old lesson new re-visited.
Dempke, W. C. M. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.01 · Cited by 2
RTOG 94-10: Keenly Awaited Results Validating the Best Therapeutic Strategy for Locally Advanced Non-Small Cell Lung Cancer
Fournel, P. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr348 · Cited by 2
Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates
Lilleby, W. A., Solca, F., & Redalen, K. R. (2010) · Oncology Reviews · doi:10.1007/s12156-010-0070-z · Cited by 2
Combining Systemic Therapies with Radiation in Non-small Cell Lung Cancer
Adamowicz, K., & Goszczyńska-Matysiak, E. (2015) · Klinicka onkologie · doi:10.14735/amko2015321 · Cited by 2
Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
Luo, Y., Lee, Y., Whang‐Peng, J., & Chen, Y. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.6323/jcrp.2015.2.3.01 · Cited by 2
Guide to Targeted Therapies: EGFR mutations in NSCLC
Cappuzzo, F. (2014) · Springer eBooks · doi:10.1007/978-3-319-03059-3 · Cited by 3
From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?
Alongi, F., Arcangeli, S., Ramella, S., Giaj‐Levra, N., Borghetti, P., D’Angelillo, R. M., Ricchetti, F., Maddalo, M., Mazzola, R., Trovò, M., et al. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1273111 · Cited by 2
A new standard of care for patients with surgically unresectable stage III non–small cell lung cancer
Gill, H. S., & Ramalingam, S. S. (2019) · Cancer · doi:10.1002/cncr.31996 · Cited by 2
Non–Small Cell Lung Cancer
Wagner, H., & Langer, C. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00044-7 · Cited by 2
Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: Focus on Non-small Cell Lung Cancer (2010)
Stinchcombe, T. E., Baggstrom, M. Q., Somaiah, N., Simon, G. R., & Govindan, R. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fd789d · Cited by 2
Management of Locally Advanced Non-Small Cell Lung Cancer
Shiarli, A.-M., Patel, P. H., & McDonald, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00206-7 · Cited by 2
Treatment of Stage III Non-small Cell Lung Cancer
Kitazawa, S., Gregor, A., & Yasufuku, K. (2023) · Respiratory medicine · doi:10.1007/978-3-031-38412-7_7 · Cited by 2
Two Decades of (Mostly) Disappointments in Definitive Chemoradiation for Stage III Non-Small Cell Lung Cancer
Park, J. H. (2018) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2018.10.555780 · Cited by 1
Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?
Grève, J. D., Decoster, L., van Brummelen, D., Geers, C., & Schallier, D. C. C. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.06.04 · Cited by 1
La longue marche de la radiothérapie thoracique : une route de 40 années vers l’espoir
Houtte, P. V., Roelandts, M., & Mornex, F. (2014) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2014.07.144 · Cited by 1
La stratégie de maintenance en première ligne de traitement dans les cancers bronchiques non à petites cellules avancés
Pérol, M., Odier, L., & Arpin, D. (2010) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(10)70078-1 · Cited by 1
Radiosensitizing Biological Modifiers Enhancing Efficacy in Non-Small-Cell Lung Cancer Treated with Radiotherapy
Holgersson, G., Bergström, S. N., Ekman, S., Brattström, D., Henriksson, R., Edlund, P., & Bergqvist, M. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.25 · Cited by 1
Place du chimiothérapeute
Westeel, V. (2008) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(08)82013-x · Cited by 1
TARGETED THERAPIES IN NON-SMALL CELL LUNG CANCER: WHICH IMPLICATION IN ROUTINE PRACTICE
Meert, A., & Berghmans, T. (2012) · Toraks Cerrahisi Bulteni · doi:10.5152/tcb.2012.26 · Cited by 1
The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
Ahn, M., Sun, J., Ahn, J. S., & Park, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8001 · Cited by 1
Early-stage non-small-cell lung cancer: overview of adjuvant chemotherapy and promising advances
Matsangou, M., Santos, E. S., Raez, L. E., Gomez, J. E., Dinh, V., & Savaraj, N. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.64 · Cited by 1
Personalized Medicine: Development of a Predictive Computational Model for Personalized Therapeutic Interventions
Kureshi, N. (2013) · DalSpace (Dalhousie University) · Cited by 1
Strahlentherapie des lokal fortgeschrittenen Lungenkarzinoms
Flentje, M. P., & Kleine, P. (2011) · Der Pneumologe · doi:10.1007/s10405-011-0499-1 · Cited by 1
EVOLUTION OF BIOLOGICAL THERAPIES IN NON-SMALL CELL LUNG CANCER
White, S. C., & Pavlakis, N. (2008) · Cancer Forum · Cited by 1
Neoadjuvant combination chemotherapy for unresectable stage III non–small cell lung cancer
Bunn, P. A., Gaspar, L. E., Weyant, M. J., & Mitchell, J. D. (2015) · Cancer · doi:10.1002/cncr.29797 · Cited by 1
Self-citation
Targeted therapy in nonsmall cell lung cancer
Heigener, D. F., Reck, M., & Gatzemeier, U. (2009) · European Respiratory Society eBooks · doi:10.1183/1025448x.00044016 · Cited by 1
Unresectable stage III non-small-cell lung cancer: Have we made any progress?
Tollenaere, C. D. (2015) · World Journal of Respirology · doi:10.5320/wjr.v5.i2.140 · Cited by 1
Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.
Neal, J. W., & Sequist, L. V. D. (2013) · Europe PMC (PubMed Central) · doi:10.3978/asvide.2014.198 · Cited by 1
Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505)
Yoon, S., Lee, K. H., & Kim, S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.09.12 · Cited by 1
To Treat or Not to Treat: When Is Adjuvant EGFR TKI Therapy Appropriate?
Asmar, R., & Halmos, B. (2015) · American Journal of Hematology / Oncology® · Cited by 1
A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401
Ninomiya, K., Yokoyama, T., Hotta, K., Oze, I., Katsui, K., Hata, T., Yoshioka, H., Bessho, A., Hosokawa, S., Kuyama, S., et al. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06092-1 · Cited by 1
Cancers bronchiques de stade III : rôle de l’onco-radiothérapeute
Lievens, Y. N., Giraud, P., Finn, C. F., Gustin, P., & Pechoux, C. L. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00103-8 · Cited by 1
Lung Cancer
Peters, S., & Zimmermann, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_3 · Cited by 1
Oncology Scan – Thoracic Cancers
Machtay, M. X. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(12)00619-0 · Cited by 1
Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
Ren, F., Wang, Y., Gao, Y., & Meng, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971192 · Cited by 1
Optimizing Drug Therapies in the Maintenance Setting After Radiochemotherapy in Non-small Cell Lung Cancer
Lin, S. H., & Raben, D. (2023) · Medical radiology · doi:10.1007/174_2022_321 · Cited by 1
Traitement standard des stades III non résécables
Fournel, P., Désage, A.-L., Saint-Gaudens, A. B., Haberer-Guillerm, S., Zalcman, G., & Ricordel, C. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00136-2 · Cited by 1
Lung Cancer
Berchem, G., & Peters, S. (2024) · Springer eBooks · doi:10.1007/978-3-030-93702-7_3-1 · Cited by 1
Cancers bronchiques non à petites cellules de stade III : quel abord local optimal ?
Wolf, J. D., Pechoux, C. L., & Berghmans, T. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00078-8 · Cited by 1
Perioperative Treatment in EGFR ‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives
Guo, X., Liu, X., Guo, C., Miao, Q., Cheng, X., Hong, X., Li, H., Qiu, X., Xiang, Y., Di, Z., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70018 · Cited by 1
[Gefitinib in Advanced Non-small-cell Lung Cancer.].
Zhu, L.-N., Yang, Z., & Wang, S. (2009) · PubMed · doi:10.3779/j.issn.1009-3419.2009.05.011 · Cited by 1
Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC.
McDonald, F., & Popat, S. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.12.05 · Cited by 1
The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer
Rafii, S. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s11542 · Cited by 1
Afatinib after Disease Progression with Gefitinib in Advanced Adenocarcinoma of the Lung
Belz, S., & Grima, G. (2013) · Journal of Pharmacy Practice and Research · doi:10.1002/j.2055-2335.2013.tb00238.x · Cited by 1
Targeted therapy for locally advanced non-small-cell lung cancer with EGFR mutation
Ragulin, Y. А., Смоленов, Е. И., Usachev, V. S., & Afonin, G. V. (2016) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20165248-53 · Cited by 1
Have adjuvant tyrosine kinase inhibitors lost their shine?
Sabari, J. K., & Chaft, J. E. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.18 · Cited by 1
Management of Locally Advanced Lung Cancer
Choy, H., & Mendel, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00004-3 · Cited by 1
Acute and Late Toxicities of Thoracic Radiotherapy
Belderbos, J. S. A., Gaspar, L. E., Demiral, A. N., & Marks, L. B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00042-1 · Cited by 1
Self-citation
A case report of sustained clinical remission in patients with locally advanced lung adenocarcinoma after sequential immunotherapy following concurrent chemoradiotherapy
Chen, W., Zhang, H., Huang, W.-F., & Lan, T. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1773 · Cited by 1
Radiotherapy and Third Generation Concurrent Chemotherapy Agents
Bland, R. E., Iyengar, P., & Choy, H. (2011) · Medical radiology · doi:10.1007/174_2011_269 · Cited by 1
Treatment Advances in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Surmont, V. F. M. (2010) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1
Lung cancer – ASCO 2010
Pall, G. (2010) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-010-0228-1 · Cited by 1
Combining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer
Bastos, B. R., & Lilenbaum, R. (2010) · Therapy · doi:10.2217/thy.10.88 · Cited by 1
Molekulare Onkologie
Hatina, J., Fínek, J., Novotna, V., Müller-Mattheis, V., & Schulz, W. A. (2012) · Der Onkologe · doi:10.1007/s00761-012-2336-5 · Cited by 1
Early Stopping of Clinical Trials
Redman, M. W. (2012) · Chapman & Hall/CRC eBooks · doi:10.1201/b11800-19 · Cited by 1
Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
Lemmon, C. A., & Pennell, N. A. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1817 · Cited by 1
NeoIntercal: Studienkonzept
Griesinger, F., Tiemann, M., Passlick, B., Reinmuth, N., Waller, C. F., Graeven, U., Reck, M., Grohé, C., Serke, M. H., Greiner, S., et al. (2017) · Forum · doi:10.1007/s12312-017-0214-1 · Cited by 1
Overview
Bogart, J. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00082-4 · Cited by 1
Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer
Edelman, M. J., & Ijaz, N. (2011) · Medical radiology · doi:10.1007/174_2011_312 · Cited by 1
Translational Research in Head and Neck Oncology
Yoo, D. S., & Brizel, D. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9464-6_11
Erhaltungstherapie oder „treatment holiday“ nach Erstlinientherapie
Serke, M. H. (2011) · Der Onkologe · doi:10.1007/s00761-011-2037-5
Optimization of radiotherapy in locally advanced lung cancer
Hallqvist, A. (2011) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Tyrosinkinaseinhibitoren beim nichtkleinzelligen Lungenkarzinom
Heigener, D. F. (2009) · Onkopipeline · doi:10.1007/s15035-009-0155-y
Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib
Naito, Y., & Goto, K. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2122
Association des thérapeutiques ciblées anti-EGFR avec la radio-chimiothérapie chez les patients présentant un cancer bronchique non à petites cellules localement avancé
Arpin, D., & Pourel, N. (2012) · ONCOLOGIE · doi:10.1007/s10269-012-2153-x
Le traitement de maintenance dans les cancers bronchiques non à petites cellules (CBNPC)
Bouyahia, N., Daoudi, K., Benbrahim, Z., Ziani, F. Z., Arifi, S., & Mellas, N. (2014) · Research · doi:10.13070/rs.fr.1.737
Radio-chimiothérapie optimale : questions résolues et non-résolues en 2012
Fournel, P., Devanlay, C., Vassal, C., & Magné, N. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70297-5
Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer
Wilson, C. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s9974
Prise en charge des CBNPC de stade III : la radiochimiothérapie concomitante
Fournel, P., Cartier, L., & Pacaut, C. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72512-1

Authors: Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R.
Affiliations: Sunnybrook Health Science Centre (CA)
ORCID: Kelly, Karen
Albain, Kathy S.
Ung, Yee C.
Gandara, David R.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2450-2456
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.4824
OpenAlex: W2153865661
Cited by: 573
References: 31
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 18 · 2022: 11 · 2021: 31 · 2020: 24 · 2019: 22 · 2018: 39 · 2017: 24 · 2016: 41 · 2015: 40 · 2014: 44 · 2013: 57 · 2012: 41
FWCI: 48.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Sanofi
National Institutes of Health (2u10ca038926-25, 5r01ca037663-18)
National Cancer Institute (CA35192, U10CA004919, CA 35176, CA-11083, CA52654, CA-45377, U10CA035261, CA35281, CA 74811, CA-35261, CA-46282, CA 20319, CA-32102, U10CA074647, CA 45450, CA35119, CA 42777, U10CA045377, CA04919, U10CA058882, U10CA074811, U10CA014028, U10CA045560, U10CA063848, U10CA035178, CA 74647, U10CA045808, CA35128, CA46368, CA46441, CA 63845, U10CA046368, CA45808, CA 45461, CA67575, U10CA035090, CA 14028, U10CA020319, U10CA086780, U10CA011083, CA-58882, CA35178, CA-45807, U10CA013612, CA 37663, U10CA035119, U10CA063850, CA35431, U10CA032102, U10CA046282, U10CA045461, U10CA052654, U10CA045450, U10CA042777, U10CA035281, CA 13612, U10CA063845, U10CA045807, U10CA063844, U10CA035431, CA-35262, U10CA035192, CA 38926, U10CA035262, CA63844, CA86780, U10CA035176, U10CA035128, CA-63850, CA-63848, CA45560, U10CA067575, CA-35090, U10CA046441)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: gefitinib, maintenance therapy, non-small cell lung cancer, stage III NSCLC, inoperable lung cancer, concurrent chemoradiotherapy, cisplatin, etoposide, thoracic radiotherapy, EGFR tyrosine kinase inhibitors, survival, toxic death
MeSH terms: Docetaxel, Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Etoposide, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Quinazolines, Remission Induction, Survival Rate, Maximum Tolerated Dose, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks